Key facts
- Starpax Biopharma’s last known valuation is $450.0M (Feb 2025).
- It has raised $72.8M; the latest was PE Growth/Expansion in Feb 2025.
- Notable investors include Kairos Capital Management.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Starpax Biopharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Starpax Biopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Starpax Biopharma
Developer of cancer treatment services intended for solid tumors while preserving organ function and avoiding traditional treatment side effects. The company offers medication-loaded bacteria that navigate the tumor in 3D, enabling drug delivery into tumors, including hypoxic zones, while preventing systemic circulation.
- Sector
- Healthcare
- HQ
- Montreal, Canada
- Founded
- 2017
- Employees
- 450
- Website
- starpaxbiopharma.com/
- Ownership
- Privately Held (backing)
Starpax Biopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Starpax Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Starpax Biopharma in its N-PORT filings yet. We sweep new filings monthly.